Edition:
United Kingdom

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

13.58USD
12 Dec 2017
Change (% chg)

$-0.26 (-1.88%)
Prev Close
$13.84
Open
$13.54
Day's High
$13.58
Day's Low
$13.28
Volume
11,208
Avg. Vol
--
52-wk High
$20.35
52-wk Low
$12.54

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.84
Market Cap(Mil.): kr.3,751.36
Shares Outstanding(Mil.): 30.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

07 Dec 2017

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

08 Nov 2017

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

02 Nov 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

24 Oct 2017

New Zealand forestry a first test in nationalist party's protectionist agenda

WELLINGTON Some New Zealand forest owners are suspending replanting of trees and re-thinking investments as the country's third-largest export earner finds itself in the sights of maverick politician Winston Peters' protectionist agenda.

10 Oct 2017

BRIEF-Zealand Pharma to cooperate with Torrey Pines Institute for Molecular Studies

* REG-ZEALAND PHARMA AND TORREY PINES INSTITUTE FOR MOLECULAR STUDIES ANNOUNCE RESEARCH COLLABORATION

04 Oct 2017

BRIEF-Zealand Pharma and Orbit Discovery enter into research collaboration

* REG-ZEALAND AND ORBIT DISCOVERY ENTER INTO RESEARCH COLLABORATION

07 Sep 2017

BRIEF-Zealand Pharma to present at Morgan Stanley Global Healthcare Conference

* REG-ZEALAND PHARMA TO PRESENT AT MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE IN NEW YORK ON SEPTEMBER 12, 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Sep 2017

BRIEF-Zealand Pharma Q2 operating loss widens to DKK 94.8 mln

* H1 REVENUE OF DKK 88.4 MILLION/USD 13.6 MILLION (DKK 14.7 MILLION/USD 2.2 MILLION IN FIRST HALF OF 2016)

24 Aug 2017

BRIEF-Zealand Pharma partner starts Phase 1 trials for two novel treatments

* PHASE 1 TRIALS FOR TWO NOVEL TREATMENTS OF OBESITY AND/OR DIABETES INITIATED BY ZEALAND PARTNER BOEHRINGER INGELHEIM

22 Aug 2017

Earnings vs. Estimates